Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.71 |
| ▸ | HTR2A | P28223 | 9/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.67 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837316 | 0.83 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5837495 | 0.83 | SLC6A4 (0.71) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL5837104 | 0.81 | SLC6A4 (0.74) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6740275 | 0.81 | SLC6A4 (0.74) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5837285 | 0.81 | SLC6A4 (1.00) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL5837785 | 0.80 | SLC6A4 (0.97) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6152232 | 0.77 | SLC6A4 (0.66) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5837752 | 0.77 | SLC6A4 (0.83) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5837060 | 0.76 | SLC6A4 (0.67) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL5836839 | 0.76 | SLC6A4 (0.67) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029972-A1 | Combination treatment for depression | HOWARD HARRY R (US) | 2004-02-12 | — | — | US | claimed |
| US-20020183306-A1 | Combination treatment for sleep disorders including sleep apnea | PFIZER INC. | 2002-12-05 | — | — | US | claimed |
| EP-1262197-A2 | Combination treatment for sleep disorders including sleep apnea | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| US-20020165217-A1 | Combination treatment for anxiety and depression | PFIZER INC. | 2002-11-07 | — | — | US | claimed |
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| US-6436938-B1 | ADMINISTERING A SIGMA RECEPTOR LIGAND IN COMBINATION WITH AN ANTIDEPRESSANT AGENT; ESPECIALLY FOR REFRACTORY DEPRESSION | PFIZER INC. | 2002-08-20 | — | — | US | claimed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | claimed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | claimed |
| US-7084165-B2 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-20040029972-A1 | Combination treatment for depression | HOWARD HARRY R (US) | 2004-02-12 | — | — | US | disclosed |
| US-6677378-B2 | AS SEROTONIN, NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS, FOR THERAPY OF CENTRAL NERVOUS SYSTEM AND OTHER DISORDERS | PFIZER INC. | 2004-01-13 | — | — | US | disclosed |
| EP-1230921-A1 | Combination treatment for depression | Pfizer Products Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| US-20020099045-A1 | Combination treatment for depression | PFIZER PRODUCTS INC. | 2002-07-25 | — | — | US | disclosed |
| EP-1224930-A1 | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression | Pfizer Products Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1154984-A1 | INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050380-A1 | MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165217-A1 | Combination treatment for anxiety and depression | GABRA1, GABRA2, GABRA5 | SLC6A4 40/4885HTR2A 48/4885KCNH2 840/4885 |
| US-20020183306-A1 | Combination treatment for sleep disorders including sleep apnea | HTR1A, HTR2A, ADRA2A | SLC6A4 30/4885HTR2A 2/4885KCNH2 700/4885 |
| US-20020107244-A1 | An antidepressant formulation consists of a biphenoxy or binaphthelenoxy compound as antidepressant, a 5-HT3 receptor antagonist and a carrier | HTR3A, HTR3E, HTR4 | SLC6A4 19/4885HTR2A 11/4885KCNH2 2974/4885 |
| US-20040029972-A1 | Combination treatment for depression | HTR3A, HTR5A, HTR6 | SLC6A4 14/4885HTR2A 9/4885KCNH2 1815/4885 |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | OPRM1, SLC6A2, OPRK1 | SLC6A4 13/4885HTR2A 43/4885KCNH2 1285/4885 |
| US-20020123490-A1 | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis | SLC6A3, OXTR, OPRD1 | SLC6A4 5/4885HTR2A 13/4885KCNH2 1532/4885 |
| US-20020099045-A1 | Combination treatment for depression | HTR5A, HTR1A, OPRL1 | SLC6A4 11/4885HTR2A 4/4885KCNH2 1516/4885 |
| US-20020147206-A1 | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | PMP22, GAP43, SLC6A2 | SLC6A4 4/4885HTR2A 108/4885KCNH2 368/4885 |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A3, SLC18A2 | SLC6A4 4/4885HTR2A 14/4885KCNH2 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.